Association between the systemic immune inflammation index and recurrence or metastasis after interventional therapy in patients with primary liver cancer- a retrospective cohort study.

Content Provider	Europe PMC
Author	Yu, Libao Zheng, Sheng Yang, Juan Fu, Zhipeng Zhu, Xing Su, Ke
Copyright Year	2023
Abstract	BackgroundThe systemic immune inflammation index has been used to evaluate the prognosis of patients with a variety of malignant tumors. However, studies were limited in primary liver cancer (PLC) patients. This study aimed to investigate the association between the systemic immune inflammation index and recurrence or metastasis after interventional therapy in patients with PLC.MethodsFrom January 2016 to December 2017, 272 patients with PLC admitted to the 941st Hospital of PLA Joint Logistics Support Force were retrospectively collected. All patients received interventional treatment, there were no residual lesions after interventional treatment. The patients were followed up for 5 years to monitor the rates of recurrence or metastasis. The patients were divided into a recurrence or metastasis group (n=112) and a control group (n=160). The differences in clinical features between the 2 groups were compared, and the predictive value of systemic immune inflammation index on recurrence or metastasis after interventional treatment in patients with PLC was analyzed.ResultsCompared with the control group (8.12%), the proportion of patients with ≥2 lesions in the recurrence or metastasis group (19.64%) was significantly increased (P=0.005); the proportion of patients with vascular invasion was significantly increased in the recurrence or metastasis group (10.71% vs. 4.38%, P=0.044); albumin decreased significantly in the recurrence or metastasis group (39.69±6.17 vs. 41.69±6.82 g/L, P=0.014); neutrophils (%) were significantly increased in the recurrence or metastasis group (0.70±0.08 vs. 0.64±0.08, P<0.001); lymphocytes (%) were significantly reduced in the recurrence or metastasis group (0.25±0.06 vs. 0.30±0.06, P<0.001); and platelet count was significantly increased in the recurrence or metastasis group (179.22±39.52 vs. 160.81±34.13 109/L, P<0.001). The systemic immune inflammation index was significantly increased in the recurrence or metastasis group (535.23±174.05 vs. 357.84±120.21, P<0.001). Systemic immune inflammation index was valuable in predicting recurrence or metastasis, and the area under the curve was 0.795 (95% CI: 0.742–0.848, P<0.001). Systemic immune inflammation index >405.08 was an independent risk factor of recurrence or metastasis [relative risk (95% CI: 1.878–5.329), P=0.000].ConclusionsElevated systemic immune inflammation index is associated with recurrence or metastasis after interventional therapy in patients with PLC.
Related Links	https://europepmc.org/backend/ptpmcrender.fcgi?accid=PMC10186503&blobtype=pdf
ISSN	20786891
Journal	Journal of Gastrointestinal Oncology [J Gastrointest Oncol]
Volume Number	14
DOI	10.21037/jgo-23-104
PubMed Central reference number	PMC10186503
Issue Number	2
PubMed reference number	37201071
e-ISSN	2219679X
Language	English
Publisher	AME Publishing Company
Publisher Date	2023-04-26
Access Restriction	Open
Rights License	Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license). See: https://creativecommons.org/licenses/by-nc-nd/4.0. 2023 Journal of Gastrointestinal Oncology. All rights reserved.
Subject Keyword	Primary liver cancer (PLC) systemic immune inflammation index interventional therapy recurrence metastasis
Content Type	Text
Resource Type	Article
Subject	Gastroenterology Oncology